Overview

A Study of Ascending Multiple Doses of Oral Surotomycin in Healthy Participants (MK-4261-009)

Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
This study aims to assess the safety, tolerability, and pharmacokinetics (PK) of oral doses of surotomycin (CB-183,315) administered for 14 consecutive days in healthy males and females.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.